{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:36:41Z","timestamp":1794663401271,"version":"4.9.1"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.antiviral.2015.06.008","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T16:24:30Z","timestamp":1434471870000},"page":"47-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":231,"special_numbering":"C","title":["Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities"],"prefix":"10.1016","volume":"121","author":[{"given":"Robert G.","family":"Gish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Given","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Locarnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson Y.N.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schluep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.06.008_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12072-014-9598-5","article-title":"High rate of core promoter and precore mutations in patients with chronic hepatitis B","volume":"9","author":"Baqai","year":"2015","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2015.06.008_b0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2015.06.008_b0015","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.dld.2014.01.024","article-title":"HAPs hepatitis B virus (HBV) capsid inhibitors prevent HBc interaction with the viral minichromosome and selected host cell genes to inhibits transcription and affect cccDNA stability","volume":"46","author":"Belloni","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.06.008_b0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/v1020091","article-title":"HBV-specific adaptive immunity","volume":"1","author":"Bertoletti","year":"2009","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2015.06.008_b0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2013.01.006","article-title":"Chronic hepatitis B: what should be the goal for new therapies","volume":"98","author":"Block","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.008_b0030","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2015.06.008_b0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00370001","article-title":"Localization of hepatitis B virus core protein and viral DNA at the nuclear membrane","volume":"12","author":"Bock","year":"1996","journal-title":"Virus Genes"},{"issue":"963\u2013973","key":"10.1016\/j.antiviral.2015.06.008_b0040","first-page":"e969","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0045","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/hep.21077","article-title":"Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study","volume":"43","author":"Bortolotti","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0060","first-page":"175","article-title":"Antiviral treatment for chronic hepatitis B virus infection \u2013 immune modulation or viral suppression","volume":"64","author":"Buster","year":"2006","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0065","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","article-title":"Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation","volume":"56","author":"Cai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.06.008_b0070","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0075","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0080","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.bpg.2008.11.003","article-title":"Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success","volume":"22","author":"Chien","year":"2008","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0085","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.510300313","article-title":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group","volume":"30","author":"Chien","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrgastro.2009.107","article-title":"Hepatitis B virus variants","volume":"6","author":"Chotiyaputta","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0095","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/jhep.2003.50352","article-title":"Prevalence of HBV precore\/core promoter variants in the United States","volume":"38","author":"Chu","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.it.2006.11.002","article-title":"IL-12p40: an inherently agonistic cytokine","volume":"28","author":"Cooper","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0105","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs","volume":"18","author":"Cradick","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2015.06.008_b0110","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(70)90926-8","article-title":"Virus-like particles in serum of patients with Australia-antigen-associated hepatitis","volume":"1","author":"Dane","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.06.008_b0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0016-5085(84)90406-2","article-title":"Spontaneous reactivation of chronic hepatitis B virus infection","volume":"86","author":"Davis","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0120","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro","volume":"46","author":"Delaney","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.06.008_b0125","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","article-title":"Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays","volume":"95","author":"Der","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2015.06.008_b0130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.06.008_b0135","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","article-title":"Temporal analysis of early immune responses in patients with acute hepatitis B virus infection","volume":"137","author":"Dunn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/oxfordjournals.aje.a115102","article-title":"Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: a large population survey","volume":"129","author":"Dusheiko","year":"1989","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"EASL","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0150","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/gut.2004.060327","article-title":"Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D","volume":"54","author":"Erhardt","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.008_b0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hep.1840060203","article-title":"Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B","volume":"6","author":"Fattovich","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2008.12.010","article-title":"Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease","volume":"286","author":"Feitelson","year":"2009","journal-title":"Cancer Lett."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.06.008_b0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/liv.12749","article-title":"HBV and the immune response","volume":"35","author":"Ferrari","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.06.008_b0170","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/gut.2004.062208","article-title":"Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferon alpha-2b therapy","volume":"54","author":"Flink","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.008_b0175","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/ajg.2009.204","article-title":"To \u201cBe\u201d or not to \u201cBe\u201d: that is the question","volume":"104","author":"Frenette","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0180","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.06.008_b0185","first-page":"61","article-title":"Assembly of hepadnaviral virions and subviral particles","volume":"168","author":"Ganem","year":"1991","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0190","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection\u2013natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0195","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/14712590902911412","article-title":"From lab to bedside: emerging clinical applications of thymosin alpha 1","volume":"9","author":"Goldstein","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.antiviral.2015.06.008_b0200","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1099\/0022-1317-81-10-2341","article-title":"Interferons: cell signaling, immune modulation, antiviral responses, and virus countermeasures","volume":"81","author":"Goodbourn","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0205","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/epi.6.6.15815","article-title":"HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state","volume":"6","author":"Guo","year":"2011","journal-title":"Epigenetics"},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2015.06.008_b0210","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1136\/gut.38.Suppl_2.S18","article-title":"Epidemiology of hepatitis B infection in the Western Pacific and South East Asia","volume":"38","author":"Gust","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.008_b0215","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0220","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/jhep.2001.27834","article-title":"Hepatitis B e antigen-negative chronic hepatitis B","volume":"34","author":"Hadziyannis","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0225","first-page":"23","article-title":"Treatment of HBe antigen-positive chronic hepatitis b","author":"Heathcote","year":"2003","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.06.008_b0230","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1038\/ncomms7588","article-title":"Trained immunity in newborn infants of HBV-infected mothers","volume":"6","author":"Hong","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2015.06.008_b0235","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0240","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-94-6-744","article-title":"Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis","volume":"94","author":"Hoofnagle","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0245","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0250","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/17460794.1.2.189","article-title":"Pathogenetic and antiviral immune responses against hepatitis b virus","volume":"1","author":"Iannacone","year":"2006","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0255","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cld.2010.05.005","article-title":"Antiviral therapy for chronic hepatitis B","author":"Jafri","year":"2010","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.06.008_b0260","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.06.008_b0265","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1177\/147323001003800620","article-title":"Effect of thymosin-alpha(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B","volume":"38","author":"Jiang","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.antiviral.2015.06.008_b0270","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1038\/emi.2013.56","article-title":"Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention","volume":"2","author":"Jones","year":"2013","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.antiviral.2015.06.008_b0275","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1440-1746.2002.02737.x","article-title":"Hepatitis B viral genotypes: clinical relevance and molecular characteristics","volume":"17","author":"Kao","year":"2002","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0280","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1136\/gut.38.Suppl_2.S31","article-title":"Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa","volume":"38","author":"Kew","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.008_b0285","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1136\/gut.38.Suppl_2.S5","article-title":"The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa","volume":"38","author":"Kiire","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.008_b0290","doi-asserted-by":"crossref","first-page":"935295","DOI":"10.1155\/2013\/935295","article-title":"Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection","volume":"2013","author":"Kondo","year":"2013","journal-title":"ISRN Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0295","doi-asserted-by":"crossref","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","article-title":"Combination of DNA prime\u2013adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model","volume":"9","author":"Kosinska","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.06.008_b0300","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24804","article-title":"Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0305","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cld.2012.03.003","article-title":"Chronic hepatitis B infection","volume":"16","author":"Kuo","year":"2012","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.06.008_b0310","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0315","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0320","first-page":"1090A","article-title":"Profound reduction in HBV covalently closed circular DNA with long-term nucleosid\/tide analogue therapy","volume":"60","author":"Lai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0325","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep.27731","article-title":"The royal wedding in chronic hepatitis B: the haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy","volume":"61","author":"Lampertico","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0330","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7 induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0335","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0340","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2015.06.008_b0345","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JVI.01957-10","article-title":"The arginine clusters of the carboxy-terminal domain of the core protein of hepatitis B virus make pleiotropic contributions to genome replication","volume":"85","author":"Lewellyn","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0350","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2015.06.008_b0355","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/gutjnl-2013-305785","article-title":"Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.008_b0360","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/0016-5085(87)90613-5","article-title":"Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection","volume":"92","author":"Lok","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0365","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0370","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2012.12.008","article-title":"Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes","volume":"97","author":"Lucifora","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.008_b0375","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.06.008_b0380","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jit561","article-title":"Compromised function of natural killer cells in acute and chronic viral hepatitis","volume":"209","author":"Lunemann","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.06.008_b0385","first-page":"478A","article-title":"REP 9 AC: a potent HBsAg release inhibitor that elicits durable immunological control of chronic HBV infection","volume":"54","author":"Mahtab","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0390","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0395","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0400","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0168-8278(08)60105-1","article-title":"Virological and biochemical response in patients with HBeAg-negative chronic hepatitis b treated with peginterferon alfa-2a (40KD) with or without lamivudine: results of 4-year follow-up","volume":"48","author":"Marcellin","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0405","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","author":"Martin","year":"2014","journal-title":"Gut"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.06.008_b0410","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2005-915644","article-title":"Epidemiology and natural history of hepatitis B","volume":"25","author":"McMahon","year":"2005","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.06.008_b0415","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.06.008_b0420","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7326\/0003-4819-135-9-200111060-00006","article-title":"Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus","volume":"135","author":"McMahon","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0425","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2105\/AJPH.89.1.14","article-title":"Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994","volume":"89","author":"McQuillan","year":"1999","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.antiviral.2015.06.008_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B","author":"Menne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0435","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","article-title":"Hepatitis B viruses: reverse transcription a different way","volume":"134","author":"Nassal","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2015.06.008_b0440","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1126\/science.1074900","article-title":"Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection","volume":"297","author":"Nguyen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.06.008_b0445","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0450","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.06.008_b0455","doi-asserted-by":"crossref","first-page":"11618","DOI":"10.3748\/wjg.v20.i33.11618","article-title":"Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways","volume":"20","author":"Pei","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"221\u2013244","key":"10.1016\/j.antiviral.2015.06.008_b0460","first-page":"e223","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0465","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","article-title":"Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B","volume":"36","author":"Perrillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0470","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0475","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.4049\/jimmunol.169.10.5827","article-title":"A unique mechanism for innate cytokine promotion of T cell responses to viral infections","volume":"169","author":"Pien","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0480","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jhep.2014.04.036","article-title":"Occult hepatitis B infection","volume":"61","author":"Pollicino","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0485","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.3748\/wjg.v20.i20.5951","article-title":"Occult hepatitis B virus and hepatocellular carcinoma","volume":"20","author":"Pollicino","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0490","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00281-012-0327-7","article-title":"Occult HBV infection","volume":"35","author":"Raimondo","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0495","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.antiviral.2015.06.008_b0500","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0505","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1128\/CVI.00396-05","article-title":"Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B","volume":"13","author":"Riordan","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0510","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1128\/JVI.76.7.3570-3574.2002","article-title":"Inhibition of hepatitis B virus replication by interferon requires proteasome activity","volume":"76","author":"Robek","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0515","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJM197611182952105","article-title":"The virus of hepatitis, type B (first of two parts)","volume":"295","author":"Robinson","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0520","doi-asserted-by":"crossref","DOI":"10.1111\/liv.12807","article-title":"Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma","author":"Saitta","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2015.06.008_b0525","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0168-8278(00)80076-8","article-title":"Long-term follow-up of patients with anti-HBe\/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine","volume":"32","author":"Santantonio","year":"2000","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0530","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1128\/JVI.71.1.345-353.1997","article-title":"Posttranscriptional regulation of hepatitis B virus replication by the precore protein","volume":"71","author":"Scaglioni","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0535","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11901-014-0238-2","article-title":"Immunosuppression in patients with chronic hepatitis B","volume":"13","author":"Seetharam","year":"2014","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.antiviral.2015.06.008_b0540","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/hep.27805","article-title":"Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens","volume":"305","author":"Shafritz","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.06.008_b0545","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2008.10.017","article-title":"Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy","volume":"50","author":"Shouval","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0550","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jmv.1890290104","article-title":"Control of HBV and HDV infection in an isolated Pacific Island: 1. Pattern of infection","volume":"29","author":"Speed","year":"1989","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0555","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0168-8278(00)80132-4","article-title":"The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy","volume":"33","author":"Stroffolini","year":"2000","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0560","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1073\/pnas.72.11.4597","article-title":"Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles","volume":"72","author":"Summers","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2015.06.008_b0565","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Pt 12","key":"10.1016\/j.antiviral.2015.06.008_b0570","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1099\/0022-1317-76-12-3159","article-title":"The precore\/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection","volume":"76","author":"Takahashi","year":"1995","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0575","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1349-7006.2006.00299.x","article-title":"Molecular functions and biological roles of hepatitis B virus x protein","volume":"97","author":"Tang","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.antiviral.2015.06.008_b0580","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.3748\/wjg.v20.i33.11630","article-title":"Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis","volume":"20","author":"Tarocchi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0585","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0168-8278(03)00378-7","article-title":"EASL international consensus conference on hepatitis B: 13-14 september, 2002 Geneva, Switzerland consensus statement (long version)","volume":"39","author":"The EASL Jury","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0590","doi-asserted-by":"crossref","first-page":"e39179","DOI":"10.1371\/journal.pone.0039179","article-title":"PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model","volume":"7","author":"Tzeng","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.06.008_b0595","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.20128","article-title":"Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B","volume":"39","author":"van Zonneveld","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0600","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27805","article-title":"Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells","author":"Vanwolleghem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0605","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3349\/ymj.2012.53.5.875","article-title":"Hepatitis B precore protein: pathogenic potential and therapeutic promise","volume":"53","author":"Walsh","year":"2012","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.antiviral.2015.06.008_b0610","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"17","author":"Wang","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2015.06.008_b0615","series-title":"Zakim and Boyer\u2019s Hepatology: A Textbook of Liver Disease","article-title":"Replication of hepatitis B virus","author":"Warner","year":"2012"},{"key":"10.1016\/j.antiviral.2015.06.008_b0620","doi-asserted-by":"crossref","first-page":"e97579","DOI":"10.1371\/journal.pone.0097579","article-title":"AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.06.008_b0625","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.antiviral.2015.06.008_b0630","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.22751","article-title":"Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells","volume":"49","author":"Wu","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.06.008_b0635","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.1128\/JVI.00918-10","article-title":"Interferons accelerate decay of replication-competent nucleocapsid of hepatitis B virus","volume":"84","author":"Xu","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0640","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2014.04.002","article-title":"Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion","volume":"107","author":"Xu","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.008_b0650","first-page":"3","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","author":"Yan","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.antiviral.2015.06.008_b0645","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2015.06.002","article-title":"NTCP opens the door for hepatitis B virus infection","volume":"121","author":"Yan","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.008_b0655","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1136\/gut.38.Suppl_2.S37","article-title":"Perinatal transmission of hepatitis B virus infection and vaccination in China","volume":"38","author":"Yao","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.008_b0660","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1021\/jm200696v","article-title":"Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion","volume":"54","author":"Yu","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.06.008_b0665","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure","author":"Zeisel","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2015.06.008_b0670","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/oxfordjournals.aje.a113443","article-title":"Seroepidemiology of infection with hepatitis B virus in Fiji","volume":"116","author":"Zhuang","year":"1982","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2015.06.008_b0675","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","article-title":"Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss","volume":"204","author":"Zoutendijk","year":"2011","journal-title":"J. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T13:53:37Z","timestamp":1691762017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":135,"alternative-id":["S0166354215001394"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}